showed a trendp = 0.237
The mAb pretreatment showed a trend towards a similar level of protection versus contemporaneous controls (75%, p = 0.237), with 2 infections in 20 challenges.
The mAb pretreatment showed a trend towards a similar level of protection versus contemporaneous controls (75%, p = 0.237), with 2 infections in 20 challenges.